File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

TitleExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
Authors
Issue Date2001
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2001, v. 33 n. 6, p. 1527-1532 How to Cite?
AbstractA study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here: Before treatment, all patients had detectable HBeAg. HBeAg seroconversion (HBeAg-negative, anti-HBe-positive), hepatitis B virus (HBV)-DNA suppression, alanine transaminase (ALT) normalization, emergence of YMDD variant HBV, liver histology, and long-term safety were assessed. After 3 years of continuous treatment with lamivudine 100 mg daily, 40% (23 of 58) of patients achieved HBeAg seroconversion. In patients with baseline serum ALT >2× upper limit of normal (ULN), the rate of HBeAg seroconversion was 65% (17 of 26). Median serum HBV-DNA concentrations Were below the level of detection, and median ALT concentrations were within the normal range throughout 3 years of treatment. YMDD variant HBV emerged in 33 of 58 (57%) patients during the 3 years, of whom 9 (27%) achieved HBeAg seroconversion (6 after emergence of YMDD variant HBV). ALT levels and histologic scores after emergence of YMDD variant HBV did not show major deterioration. Lamivudine was well tolerated during 3 years of therapy. In conclusion, these data in Chinese patients with chronic hepatitis B show enhanced seroconversion rates with extended lamivudine treatment. Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy.
Persistent Identifierhttp://hdl.handle.net/10722/162490
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, NWYen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorChang, TTen_US
dc.contributor.authorGuan, Ren_US
dc.contributor.authorLee, CMen_US
dc.contributor.authorNg, KYen_US
dc.contributor.authorLim, SGen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorDent, JCen_US
dc.contributor.authorEdmundson, Sen_US
dc.contributor.authorCondreay, LDen_US
dc.contributor.authorChien, RNen_US
dc.date.accessioned2012-09-05T05:20:29Z-
dc.date.available2012-09-05T05:20:29Z-
dc.date.issued2001en_US
dc.identifier.citationHepatology, 2001, v. 33 n. 6, p. 1527-1532en_US
dc.identifier.issn0270-9139en_US
dc.identifier.urihttp://hdl.handle.net/10722/162490-
dc.description.abstractA study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here: Before treatment, all patients had detectable HBeAg. HBeAg seroconversion (HBeAg-negative, anti-HBe-positive), hepatitis B virus (HBV)-DNA suppression, alanine transaminase (ALT) normalization, emergence of YMDD variant HBV, liver histology, and long-term safety were assessed. After 3 years of continuous treatment with lamivudine 100 mg daily, 40% (23 of 58) of patients achieved HBeAg seroconversion. In patients with baseline serum ALT >2× upper limit of normal (ULN), the rate of HBeAg seroconversion was 65% (17 of 26). Median serum HBV-DNA concentrations Were below the level of detection, and median ALT concentrations were within the normal range throughout 3 years of treatment. YMDD variant HBV emerged in 33 of 58 (57%) patients during the 3 years, of whom 9 (27%) achieved HBeAg seroconversion (6 after emergence of YMDD variant HBV). ALT levels and histologic scores after emergence of YMDD variant HBV did not show major deterioration. Lamivudine was well tolerated during 3 years of therapy. In conclusion, these data in Chinese patients with chronic hepatitis B show enhanced seroconversion rates with extended lamivudine treatment. Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_US
dc.relation.ispartofHepatologyen_US
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAntiviral Agents - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshDelayed-Action Preparationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenetic Variation - Physiologyen_US
dc.subject.meshHepatitis B E Antigens - Analysisen_US
dc.subject.meshHepatitis B Virus - Geneticsen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Immunology - Pathology - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLamivudine - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshLiver - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshSafetyen_US
dc.subject.meshTime Factorsen_US
dc.titleExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1053/jhep.2001.25084en_US
dc.identifier.pmid11391543-
dc.identifier.scopuseid_2-s2.0-0034993211en_US
dc.identifier.hkuros59899-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034993211&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume33en_US
dc.identifier.issue6en_US
dc.identifier.spage1527en_US
dc.identifier.epage1532en_US
dc.identifier.isiWOS:000168937500023-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLeung, NWY=26643107200en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridChang, TT=7404725147en_US
dc.identifier.scopusauthoridGuan, R=7102456913en_US
dc.identifier.scopusauthoridLee, CM=24543421500en_US
dc.identifier.scopusauthoridNg, KY=7403178546en_US
dc.identifier.scopusauthoridLim, SG=7404081127en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridDent, JC=7201577625en_US
dc.identifier.scopusauthoridEdmundson, S=15723166300en_US
dc.identifier.scopusauthoridCondreay, LD=7004527800en_US
dc.identifier.scopusauthoridChien, RN=12787728600en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats